Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1703 in Eosinophilic Asthma
NCT06653322Phase 3Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2024
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1703 in eosinophilic asthma (EA), sponsored by Hengrui Therapeutics. Started Nov 2024; status: active, not recruiting.
02
Drugs
SHR-1703
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT06653322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653322.